13F Holdings
中文EN

PCVX Vaxcyte, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1649094 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-74.8%
TTM EPS YoY-66.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-42.7%
ROA-37.3%
ROIC (approx.)-39.1%
Asset turnover—

Leverage & solvency

Liabilities / assets16.7%
Debt / equity0.00x
Current ratio4.56x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$794.31M$476.64M$332.34M$169.45M$78.41M
SG&A expense$129.37M$92.90M$60.70M$39.81M$25.26M
Operating income-$923.67M-$569.55M-$468.04M-$232.26M-$103.67M
Interest expense—$0$0$2,000$7,000
Income tax$0$0$0——
Net income-$766.63M-$463.93M-$402.27M-$223.49M-$100.08M
EBITDA-$907.28M-$562.54M-$464.88M-$229.42M-$101.87M
EPS (basic)-5.63-3.80-4.14-3.44-1.93
EPS (diluted)-5.63-3.80-4.14-3.44-1.93
Dividends declared per share0.000.000.000.000.00
Weighted avg. shares (diluted)136.09M122.00M97.16M64.88M51.92M
Balance sheet
Cash & equivalents$173.96M$389.19M$397.45M$835.53M$69.86M
Short-term investments$1.39B$1.36B$682.78M$96.72M$176.99M
Current assets$1.63B$1.79B$1.10B$942.55M$256.35M
PP&E, net$257.37M$198.04M$79.63M$10.36M$7.95M
Total assets$3.00B$3.51B$1.41B$1.01B$324.34M
Current liabilities$205.75M$140.18M$145.34M$40.52M$28.72M
Total liabilities$317.21M$205.50M$167.45M$52.56M$40.32M
Shareholders' equity$2.69B$3.31B$1.24B$953.61M$284.02M
Shares outstanding131.06M124.89M95.36M79.47M53.03M
Cash flow statement
Operating cash flow-$655.58M-$452.63M-$296.79M-$170.60M-$121.39M
Capital expenditure$13.71M$22.43M$16.06M$5.84M$6.55M
Free cash flow-$669.29M-$475.05M-$312.85M-$176.44M-$127.95M
Investing cash flow$437.35M-$2.01B-$773.31M$74.58M-$212.31M
Financing cash flow$2.01M$2.45B$639.81M$861.55M$17.80M
Depreciation & amortization$16.40M$7.00M$3.16M$2.83M$1.80M
Stock-based compensation$138.84M$84.82M$48.76M$23.65M$10.73M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.